Sun Pharma to Acquire Organon in $11.75B Deal
India-based Sun Pharmaceutical Industries Ltd. has agreed to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion.
India-based Sun Pharmaceutical Industries Ltd. has agreed to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion.
Ligand Pharmaceuticals has agreed to acquire XOMA Royalty Corporation in an all-cash deal valued at approximately $739mn, doubling the size of its biotech royalty portfolio and cementing its position as one of the dominant aggregators in a…
Catalyst Pharmaceuticals, the US rare-disease drug developer, has emerged as a potential acquisition target for Italy's Angelini Pharma, in the latest sign of how aggressively European drugmakers are scouring the US market for…
A wave of analyst downgrades has hit Terns Pharmaceuticals after Merck agreed to acquire the US biotech for $6.7bn, ending one of the most striking small-cap rallies of the past year and underlining the willingness of large pharmaceutical…
Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at $6.3bn upfront, as the US drugmaker deepens its push into neuroscience and sleep-related disorders.
Acquisition creates integrated biosimilars platform as wave of biologic patent expiries approaches
OliX Pharmaceuticals, the Seoul-listed RNA interference specialist, has signed a memorandum of understanding with Galux, a South Korean artificial-intelligence drug discovery firm, to co-develop a new class of siRNA delivery platform — the…
Merck & Co. has agreed to acquire Terns Pharmaceuticals for $6.7bn, as it seeks to strengthen its oncology pipeline ahead of looming patent expiries on its top-selling drug Keytruda.